Flexible approaches to trial design – from exploratory designs that more effectively target the maximum tolerated dose, to population enrichment methods that support precision medicine, have the potential to improve efficiency and reduce risk.
Download our ebook and discover how our strategic consultancy group
helps clients create and apply innovative trial designs within
exploratory and confirmatory oncology development.
Model-Based Bayesian Design for Phase 1/2a Trial
Hybrid Model/ Rule-based Design for Phase 1 Combination Trial
Phase 2 Hematological Oncology Trial Comparing Treatment Overall Response Rate to Historical Control
Innovative Phase 3 Adaptive Enrichment Design Reduces Development Risk in Rare Oncology Indication
Combining Bayesian Decision-Making with Frequentist Final Analysis in Phase 3 Oncology Trial
Optimizing Biosimilar Development with an Adaptive Design Approach